NIPPON GLAXO PROGRAM TO MOVE ZANTAC TO OTC
- Nippon Glaxo is in Phase III trials with Zantac (ranitidine) in Japan as part of its program for gaining an over-the-counter indication for the product. The exact intended indications for the OTC version of the drug are unknown although the company is thought to be targeting symptoms such as dyspepsia. The patents for ranitidine in Japan expire in 1997 (Form 1) and 2001 (Form 2). Among other companies also aiming to gain a part of the same market, Sumitomo is furthest ahead as it has already filed an application for an OTC version of cimetidine, followed by Fujisawa Pharmaceutical, which is about to complete Phase III studies for cimetidine, and Sankyo and Taisho, which are in Phase III trials for an OTC version of ranitidine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze